Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SCT1000 in Healthy Women
NCT04921111Phase 1Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Jul 2021
- Primary completion
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant 14-valent human papillomavirus vaccine in human papillomavirus infection (2 arms), sponsored by Sinocelltech Group Limited. Primary endpoints: Occurrence of local reaction AEs, Occurrence of systemic AEs and 1 more. Status: unknown.
02
Drugs
recombinant 14-valent human papillomavirus vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT04921111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04921111.